JORDAN FROSCH: Open Payments
NPI 1215666581 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$982 in 46 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $370 · 2025 $982
Food & beverage: $982
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $172 |
| Eisai Inc. | 4 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| Mallinckrodt Hospital Products Inc. | 3 | $83 |
| Madrigal Pharmaceuticals | 3 | $69 |
| Merck Sharp & Dohme LLC | 2 | $68 |
| Intercept Pharmaceuticals, Inc. | 3 | $57 |
| Genentech USA, Inc. | 2 | $49 |
| Mirum Pharmaceuticals, Inc. | 2 | $39 |
| Alexion Pharmaceuticals, Inc. | 2 | $34 |
Products named: XIFAXAN, Lenvima, LIVTENCITY, TERLIVAZ, REZDIFFRA, OCALIVA, Tecentriq, Livmarli.
Industry payments across TX — which companies pay providers there.
